



CNIV 2016

« 1^{ER} CONGRÈS NATIONAL D'IMAGERIE DU VIVANT »

10 - 12 FÉVRIER 2016 – THÉÂTRE DU GYMNASE MARIE BELL (PARIS)

medicen | innovation
PARIS REGION for
health

IMSTAR PATHFINDER™ CELLULAR IMAGING SYSTEMS

*SMART SOLUTIONS FOR DNA DAMAGE PREVENTION AND FOR EARLY CANCER
DETECTION AND TREATMENT MANAGEMENT*



DR FRANÇOISE SOUSSALINE, FOUNDER, PRESIDENT & CEO

E-MAIL: FRANCOISE.SOUSSALINE@IMSTARSA.COM



Quantitative Cellular Imaging Solutions for Biomarkers Identification and validation in Research and Cyto-Pathology

Innovative concepts in cellular imaging and development of cutting edge image cytometry technology for preclinical research and assisted in vitro diagnostic

- IMSTAR is pioneer in the field of cellular analysis for Life Sciences research and *In Vitro* Diagnostic (IVD)
- Founded by Francoise Soussaline, an international expert in digital imaging
- Consultants and advisory board including specialists in Oncology, Toxicology, Cytopathology, Cytogenetics
- Strong links with key French and European networks in Life Sciences and Oncology personalized medicine
- Global customers base, KOLs' Academic Labs and blue chip Companies: Pharmas, Nutrition, Tobacco, Cosmetic, Cytogenetic & CytoPathology labs

01

Strong corporate culture, multidisciplinary expertise (biophysics, modeling, morphology and phenotype characterization algorithms, cell biology, medicine, and cytopathology)

02

Over 35% of its revenues invested in R&D over the past 15 years. Strong IP portfolio: 13 patents (US7092559), 98 copyrights and 15 trademarks to protect Pathfinder™

03

The Pathfinder™ range of products is compliant with


- EC Directive 98/79/EC IVD MD 
- OECD TG 487

04

IMSTAR continues to innovate, particularly in the field of **cellular tumor marker quantification**

PATHFINDER™ products

Innovative Software embedded in a Reader-Analyzer for Biomarkers assessment and validation



To provide the best in class Image Cytometry System, PATHFINDER™ ICS for

- Tumor markers fine characterization, profiling and automated abnormal cells detection for high-content cytology/pathology
- Assisted quantitative cytopathology for routine IVD
- DNA damage, chromosome alterations, rearrangements, mutations, telomeres length for predictive cytogenetic biomarkers in oncology or aging


Cost effectiveness, High-Content Analysis of tumor and rare cells offers a dramatic assistance to the Oncologist, Pathologist, Biologist or technician for faster, accurate, robust interpretation and expertise sharing, for diagnostic, prognostic and personalized therapeutic choice, therefore for the patient' benefit



CANCER EARLY DIAGNOSTIC, STAGING AND PROGNOSTIC BIOMARKERS FOR PERSONALIZED AND PREDICTIVE MEDICINE


IMSTAR Offer/Look for a consortium

- Co-development and sub-contracting in assisted in vitro diagnostic, biomonitoring and screening tool in pharma/Geno-Toxicology
 - Automated tumor cells detection in Digital Cyto-Pathology
 - Highly-parallel testing / high sample throughput
 - Virtual and distant imaging functionalities




TUMOR MARKERS Assessment


Cytology/histo/Pathology using DNA staining, IHC, IF, FISH, M-FISH... in various format




Her2 Breast cancer : Tissue ;
Cytoponction




Bladder cancer cytology
(UroVision®)




Probe co-localization 3D analysis






γ H2AX
phosphorylation signals
Detected signals
within nuclei




M-FISH Sarcoma
chromosomes
rearrangement




PARP /TUNEL
apoptosis
quantification




Lung cancer :
CTC automated
detection and
classification
using specific
FISH probes




Automated
detection of HSIL
cells in cervical LBC



Colon tumor:
lymphocyte infiltration



Prostate tumor
Proliferation Ki67 index



Hepatoma: Telomerase
activity measurement

Partnerships & Customers

IMSTAR range of products has been validated through collaborative R&D consortia: 7 EC FP5-7 and Eureka ITEA2 public-private R&D consortia (Comics, Toxdrop, Safe, NewGeneris, HiPiP, Medusa...) and French consortium (PIA NanoCTC, FUI ExpeVivo-CTC)



Contact : Dr Françoise SOUSSALINE, Founder, President & CSO

E-mail: françoise.soussaline@imstarsa.com

IMSTAR S.A. 60 Rue Notre Dame des Champs 75006 Paris, France

Phone +33 (0) 1 42 34 93 77 – Cell +33 (0) 6 15 06 51 53

www.imstarsa.com - <https://www.linkedin.com/company/1876267>